Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance

Novartis AGTrade
Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Charles Schwab Corporation Common Stock — how do they compare? Novartis AG trades at $153.14 (market cap $295.37B), while Charles Schwab Corporation Common Stock trades at $107.91 (market cap $186.25B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

NVSSCHW
Market Cap
$295.37B$186.25B
Sector
HealthFinancials
52-Week High
$168.62$108.02
52-Week Low
$119.31$85.35
Enterprise Value
$336.69B
Dividend Yield
3.07%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $107.99, up 0.36% today, near its all-time high. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels suggest overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.56 expected, and revenue growth accelerated to $23.92 billion in 2025. Analyst sentiment remains positive with a 56.87% buy rating and a $122.33 consensus price target, indicating potential upside.

The outlook for SCHW is favorable given robust earnings performance and upward revenue guidance, but risks include potential market volatility from economic data and ongoing litigation. Institutional buying and a high ROE of 22.45% support the bullish case, though investors should monitor inflation reports and insider selling activity for near-term cues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW